How has Revvity (RVTY) been performing? Here's a data-driven look at its financials, valuation, and shareholder returns.
Revenue Trend
Revvity's top line grew 3.7% to $2.86B in FY2025, compared to $2.76B in FY2024.
Over the past 10 years, revenue has grown at just 3.1% annually — from $2.10B to $2.86B. That barely keeps up with inflation.
Revvity's $2.86B revenue base puts it in the smaller bracket among US health care companies.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | $2.86B | +3.7% |
| FY2024 | $2.76B | +0.2% |
| FY2023 | $2.75B | -16.9% |
| FY2022 | $3.31B | -13.5% |
| FY2021 | $3.83B | +1.2% |
See Revvity's complete revenue history below
Revenue by Segment
Looking under the hood at Revvity's revenue mix for FY2025.
| Segment | Revenue | % of Total |
|---|---|---|
| Life Sciences | $1.43B | 50.1% |
| Diagnostics | $1.42B | 49.9% |
At 50.1% of total revenue, Life Sciences is by far Revvity's largest segment.
Notably, Life Sciences grew 14.1% YoY, taking its share to 50.1% of total revenue.
Geographically, Revvity's revenue is split across Other International (60%), United States (25%), China (9%), Germany (4%), and United Kingdom (3%).
Profitability Analysis
Net income for Revvity weakened to $241.7M in FY2025, 18.3% lower than the $295.8M posted in FY2024.
The net margin narrowed from 10.7% to 8.5%, suggesting rising cost pressures.
On a per-share basis, diluted earnings were $2.08 in FY2025 versus $2.41 in FY2024.
View Revvity's complete earnings and margin analysis
Dividends & Buybacks
In FY2025, Revvity distributed $0.29 per share in dividends (0.30% yield).
The dividend track record is notable: Revvity has maintained payouts for 10+ straight years.
With a 13.9% payout ratio, there's headroom for future dividend increases.
| Year | DPS | Payout Ratio |
|---|---|---|
| FY2025 | $0.29 | 13.9% |
| FY2024 | $0.28 | 11.6% |
| FY2023 | $0.28 | Net loss — payout ratio not meaningful |
| FY2022 | $0.28 | 6.2% |
| FY2021 | $0.28 | 3.4% |
On the buyback front, Revvity has spent $2.04B repurchasing shares over 11 years, reducing the float and boosting per-share metrics.
See how buybacks have impacted Revvity's share count over time
Revvity Debt & Liquidity
| Metric | Value |
|---|---|
| Cash & Short-term Investments | $919.9M |
| Total Debt | $3.66B |
| Shareholders' Equity | $7.25B |
| Total Assets | $12.17B |
| Debt-to-Equity Ratio | 0.51x |
| Current Ratio | 1.68x |
| Interest Coverage | 3.9x |
| Free Cash Flow (TTM) | $508.3M |
The numbers look healthy: Revvity carries $3.66B in debt against $919.9M in cash, with a comfortable D/E ratio of 0.51x.
The current ratio of 1.68x indicates Revvity can comfortably meet short-term obligations.
A 3.9x interest coverage ratio gives Revvity a moderate cushion above its debt service costs.
Strong free cash flow generation of $508.3M gives Revvity financial flexibility for capital allocation.
Explore Revvity's full balance sheet and cash flow analysis below
Revvity reported a headcount of 11,000 in FY2025, about $259.6K in revenue per employee.
Explore Revvity's headcount trend and workforce productivity
Is Revvity Fairly Valued?
Is Revvity stock overvalued or undervalued? Here's what our valuation models suggest.
Revvity shares are currently trading at $101.07.
The P/E Ratio approach puts Revvity's intrinsic value at $56, a 79.3% downside from the current market price.
We also calculate intrinsic value using the DCF and EPS Growth models. Sign up to see the full breakdown with fair value estimates.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | $56 | 79.3% downside to fair value |
| DCF | Upgrade | Upgrade |
| EPS Growth | Upgrade | Upgrade |
Key Takeaways
In summary, Revvity (RVTY) presents the following picture for fundamental analysts.
Revenue of $2.86B in FY2025, up 3.7% year-over-year.
Long-term revenue has been compounding at 3.1% annually over 10 years.
The company is profitable, with a net margin of 8.5% and net income of $241.7M.
Returned $853.6M to shareholders in FY2025 through dividends and/or buybacks.
Conservative balance sheet with a D/E ratio of 0.51x.
The P/E Ratio model implies 79.3% downside to fair value. The remaining 2 models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
See the full picture: Revvity's interactive charts, valuation models, and financial trends are below.